大学ホーム医学研究科教育・研究指導教員紹介：

教員紹介：久松　理一


氏名
 		 久松　理一
ヒサマツ　タダカズ HISAMATSU, Tadakazu
職位 教授
学内の役職・委員等 副病院長（病床管理・運営担当）
消化器内科診療科長
内視鏡センター長
炎症性腸疾患包括医療センター長

病院機能評価統括委員会委員長
未承認新規医薬品等評価委員会委員長
内視鏡運営委員会委員長
QM委員会
中長期委員会
病院CPC運営委員会

医学部倫理委員会委員長
医学研究科教務委員会
所属教室

消化器内科学教室

専攻・専門分野
　（大学院）

医学専攻 消化器内科学分野（新課程）
内科系専攻 内科学分野（消化器内科学）（旧課程）

担当科目（学部） 臨床医学入門，　M1プレチュートリアル, M3臨床講義 消化器内科学， 免疫学，CPC，BSL， 臨床総合演習
担当科目（大学院） 炎症性腸疾患の病態と進歩する分子標的治療薬について
専門分野 消化器病学、炎症性腸疾患、粘膜免疫学
研究テーマ 炎症性腸疾患の病態解明と新規治療法の確立。腸内細菌と腸管免疫の応答性。メタボローム解析を用いた炎症性腸疾患バイオマーカーの確立。マクロファージ分化における代謝の影響。難治性小腸潰瘍症の病態解明と治療法確立。
略歴 1991年　慶應義塾大学医学部卒
1991年　慶應義塾大学病院内科研修医
1993年　伊勢慶應病院内科
1994年　社会保険埼玉中央病院内科
1995年　慶應義塾大学病院内科専修医（消化器内科）
1997年　東京歯科大学市川総合病院内科　助手
2000年　米国ハーバード大学マサチューセッツ総合病院消化器科研究員
2003年　慶應義塾大学医学部内科学（消化器）助手（現助教）
2008年　慶應義塾大学医学部内科学（消化器）専任講師（学部内）
2010年　慶應義塾大学医学部内科学（消化器）専任講師
2014年　慶應義塾大学医学部内科学（消化器）　准教授
2015年　杏林大学医学部第三内科学（消化器内科）教授
2016年　杏林大学医学部付属病院消化器内科診療科長，内視鏡室長
2019年　杏林大学医学部消化器内科学　教授

現在に至る
所有する学位 博士（医学）
指導医・専門医・認定医、その他の資格等 日本内科学会指導医・総合内科専門医・認定医
日本消化器病学会指導医・専門医
日本消化器内視鏡学会指導医・専門医
日本消化管学会胃腸科指導医・専門医
日本カプセル内視鏡学会認定医
日本炎症性腸疾患学会指導医・IBD専門医
日本臨床免疫学会免疫療法認定医
日本医師会認定産業医
日本医師会ACLS研修
教養試験医学系OSCE評価者
GCP（臨床試験の実施基準）概説に関する研修
American College of Gastroenterology, FACG
The American Gastroenterological Association, AGAF
論文・著書等を含む主要研究業績 【主な英文論文】(2025.5 全285論文）
Matsuoka K, Igarashi A, Hisamatsu T, et al. Clinical characteristics of patients with difficult-to-treat ulcerative colitis: a nested case-control study using a Japanese claims database.
Intest Res. 2025 Apr 25. doi: 10.5217/ir.2024.00119.
Matsuoka K, Motoya S, Hisamatsu T, et al. Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data.
J Gastroenterol. 2025 Apr 21. doi: 10.1007/s00535-025-02249-5.
Hisamatsu T, Miyoshi J, Oguri N, et al. Inflammation-Associated Carcinogenesis in Inflammatory Bowel Disease: Clinical Features and Molecular Mechanisms.
Cells. 2025 Apr 9;14(8):567. doi: 10.3390/cells14080567.
Hisamatsu T, Miyoshi J, and Minoru M
Recent Advances in Molecular Targeted Therapy for Inflammatory Bowel Disease (Review)
Intern Med. 2025 Apr 5. doi: 10.2169/internalmedicine.5491-25.
Naganuma M, Shiga H, Hisamatsu T, et al. First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.
J Gastroenterol. 2025 Apr;60(4):430-441. doi: 10.1007/s00535-025-02216-0.
Hart A, Panaccione R, Hisamatsu T, D'Haens G, et al. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study.
Gastroenterology. 2025 Mar 18:S0016-5085(25)00522-0. doi: 10.1053/j.gastro.2025.02.033.
Ogino Y, Sadashima K, Hisamatsu T, Matsumoto T, et al, Esaki M. Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease.
J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02235-x.
Matsumoto T, Hisamatsu T, Esaki M, et al. Guidelines for endoscopic diagnosis and treatment of inflammatory bowel diseases.
Dig Endosc. 2025 Mar 3. doi: 10.1111/den.15002.
Hisamatsu T, Naganuma M, Pinton P, Takeno M. Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan.
J Gastroenterol. 2025 Mar;60(3):294-305. doi: 10.1007/s00535-024-02191-y.
Panaccione R, Ferrante M, Hisamatsu T, D'Haens G, et al. Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.
Clin Gastroenterol Hepatol. 2025 Feb 3:S1542-3565(25)00082-5. doi: 10.1016/j.cgh.2024.12.023.
Rubin DT, Allegretti JR, Hisamatsu T, Dignass A, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5.
Okabe M, Yamamoto S, Shiokawa M, Hisamatsu T, Seno H, et al. Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
J Gastroenterol. 2025 Jan;60(1):86-95. doi: 10.1007/s00535-024-02176-x.
Komatsu H, Morikubo H, Kimura Y, Moue C, Yonezawa H, Matsuura M, Miyoshi J, Hisamatsu T. Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis.
J Gastroenterol.　2025 Feb;60(2):166-173. doi: 10.1007/s00535-024-02172-1.
Takenaka K, Hisamatsu T, Ohtsuka K, Watanabe M, et al. Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn's Disease; a prospective multicenter study.
Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01084-X. doi: 10.1016/j.cgh.2024.10.030.
Ferrante M, D'Haens G, Hisamatsu T, Sands BE, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8.
Nakase H, Wagatsuma K, Hisamatsu T, et al. Involvement of Mediterranean fever gene mutations in colchicine-responsive enterocolitis: a retrospective cohort study.
EBioMedicine. 2024 Dec;110:105454. doi: 10.1016/j.ebiom.2024.105454.
Atreya R, Ferrante M, Hisamatsu T, D'Haens G, et al. Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
J Crohns Colitis. 2024 Nov 1:jjae164. doi: 10.1093/ecco-jcc/jjae164.
Oguri N, Miyoshi J, Nishinarita Y, Wada H, Nemoto N, Hibi N, Kawamura N, Miyoshi S, Lee STM, Matsuura M, Osaki T, Hisamatsu T. Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model.
NPJ Biofilms Microbiomes. 2024 Sep 16;10(1):81. doi: 10.1038/s41522-024-00564-y.
Colombel JF, Hisamatsu T, Regueiro M, et al. Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Clin Gastroenterol Hepatol. 2024 Aug;22(8):1668-1677. doi: 10.1016/j.cgh.2024.02.027.
Ohno A, Miyamoto N, Kaji R, Shirakawa T, Watanabe M, Sumi R, Jinbo Y, Kusuhara M, Miyoshi J, Hisamatsu T. The influence of color vision deficiency on vessel visibility during colorectal endoscopic submucosal dissection and the potential advantage of red dichromatic imaging to achieve color vision barrier-free.
DEN Open. 2024 Jul 19;5(1):e410. doi: 10.1002/deo2.410.
Louis E, Schreiber S, Hisamatsu T, Loftus EV Jr, et al. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414.
Afif W, Arasaradnam RP, Hisamatsu T, Marano C, et al. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Am J Gastroenterol. 2024 May 1;119(5):910-921. doi: 10.14309/ajg.0000000000002621.
Kimura Y, Miyoshi J, Morikubo H, Komatsu H, Moue C, Yonezawa H, Matsuura M, Hisamatsu T. Early sonographic improvement predicts clinical remission and mucosal healing with molecular-targeted drugs in ulcerative colitis.
Gastro Hep Advances 2024 Apr 23;3(6):703-710. doi: 10.1016/j.gastha.2024.04.007.
Naganuma M, Nakamura N, Hisamatsu T, et al. Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
J Gastroenterol. 2024 Apr;59(4):302-314. doi: 10.1007/s00535-024-02079-x.
Morikubo H, Tojima R, Maeda T, Matsuoka K, Matsuura M, Miyoshi J, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis.
Sci Rep. 2024 Feb 22;14(1):4386. doi: 10.1038/s41598-024-55126-1.
Komatsu H, Morikubo H, Kimura Y, Moue C, Yonezawa H, Matsuura M, Miyoshi J, Hisamatsu T. A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion.
J Gastroenterol. 2024 Mar;59(3):209-215. doi: 10.1007/s00535-024-02077-z.
Danese S, Panaccione R, Hisamatsu T, D'Haens GR, et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7.
Danese S, Panaccione R, Hisamatsu T, D'Haens GR, et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318-7.
Afif W, Arasaradnam RP, Hisamatsu T, Marano C, et al. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study.
Am J Gastroenterol. 2023 Dec 14.
Peyrin-Biroulet L, Allegretti JR, Hisamatsu T, Dignass A, et al. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Gastroenterology. 2023 Sep 1:S0016-5085(23)04963-6.
Naganuma M, Kobayashi T, Hisamatsu T, et al. Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
J Gastroenterol.2023 Dec;58(12):1198-1210.
Watanabe K, Nojima M, Hisamatsu T, et al. Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
J Gastroenterol.2023 Aug 10.
Matsuoka K, Yamazaki H, Hisamatsu T, et al. Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
J Gastroenterol.2023 Aug;58(8):751-765.
Wada H, Miyoshi J, Kuronuma S, Nishinarita Y, Oguri N, Hibi N, Takeuchi O, Akimoto Y, Lee STM, Matsuura M, Kobayashi T, Hibi T, Hisamatsu T. 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis.
Sci Rep. 2023 Jul 28;13(1):12241.
Ueda T, Koyama F, Hisamatsu T, et al. Endoscopic lesions of postoperative anastomotic area in patients with Crohn's disease in the biologic era: A Japanese multi-center nationwide cohort study.
J Crohns Colitis. 2023 Jul 14:jjad116.
D'Haens G, Dubinsky M, Sands BE; LUCENT Study Group (Hisamatsu.T), et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2023 Jun 29;388(26):2444-2455.
Matsuoka K, Fujii T, Hisamatsu T, et al. Correction: Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).
J Gastroenterol.2023 Jun;58(6):602-603.
Hirai M, Yanai S, Hisamatsu T, Matsumoto T, et al. The effectiveness of endoscopic resection for colorectal neoplasms in ulcerative colitis: a multicenter registration study.
Gastrointest Endosc. 2023 May 30:S0016-5107(23)02606-8.
Saito D, Hirai F, Hisamatsu T, et al. A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: the SOUL study.
Endosc Int Open. 2023 May 17;11(5):E504-E512.
Nakase H, Esaki M, Hisamatsu T, et al. Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021.
J Gastroenterol. 2023 Apr;58(4):313-345.
Ishige T, Shimizu T, Hisamatsu T, et al. Correction to: Expert consensus on vaccination in patients with inflammatory bowel disease in Japan.
J Gastroenterol. 2023 Apr;58(4):431-432.
Yamamoto T, Nakase H, Hisamatsu T, et al. Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn's Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn's Disease (iCREST-CD).
J Crohns Colitis. 2023 Mar 4:jjad038.
Nakase H, Wagatsuma K, Hisamatsu T, et al. Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey.
J Gastroenterol. 2023 Mar;58(3):205-216.
Nakase H, Hayashi Y, Hisamatsu T, et al. Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study.
Gastreo Hep Advances 2023;2:1056-1065
Ferrante M, Panaccione R, Hisamatsu T, D'Haens G, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4.
D'Haens G, Panaccione R, Hisamatsu T, Ferrante M, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet. 2022 May 28;399(10340):2015-2030.
Abreu MT, Rowbotham DS, Hisamatsu T, Marano C, et al. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
J Crohns Colitis. 2022 Mar 3:jjac030.
Nakase H, Hayashi Y, Hisamatsu T, et al. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS).
J Gastroenterol. 2022 Mar;57(3):174-184.
Sandborn WJ, D'Haens GR, Hisamatsu T, Feagan BG, et al. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology. 2022 Feb 5:S0016-5085(22)00102-0.
Miyoshi J, Ozaki R, Yonezawa H, Mori H, Kawamura N, Matsuura M, Hisamatsu T. Ratio of submucosal thickness to total bowel wall thickness as a new sonographic parameter to estimate endoscopic remission of ulcerative colitis.
J Gastroenterol. 2022 Feb;57(2):82-89. doi: 10.1007/s00535-021-01847-3.
Miura M, Shimizu H, Hisamatsu T, et al. Multicenter, cross-sectional, observational study on Epstein-Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study).
J Gastroenterol. 2021 Dec;56(12):1080-1091.
Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis.
Sci Rep. 2021 Aug 12;11(1):16440.
Sakuraba A, Nemoto N, Hibi N, Ozaki R, Tokunaga S, Kikuchi O, Minowa S, Mitsui T, Miura M, Saito D, Hayashida M, Miyoshi J, Matsuura M, Yoneyama M, Ohnishi H, Hisamatsu T. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis.
BMC Gastroenterol. 2021 May 1;21(1):197.
Nakase H, Uchino M, Hisamatsu T, Koike K, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.
J Gastroenterol. 2021 Apr 22.
Kobayashi T, Motoya S, Hisamatsu T, Hibi T, et al. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Lancet Gastroenterol Hepatol. 2021 Apr 19:S2468-1253(21)00062-5.
Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016.
J Crohns Colitis. 2021 Mar 5;15(3):358-366.
Watanabe K, Tanida S, Hisamatsu T, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.
J Gastroenterol. 2020 May 7.
Hayashida M, Miyoshi J, Mitsui T, Miura M, Saito D, Sakuraba A, Kawashima S, Ikegaya N, Fukuoka K, Karube M, Komagata Y, Kaname S, Okada AA, Fujimori S, Matsuura M, Hisamatsu T. Elevated fecal calprotectin and lactoferrin are associated with small intestinal lesions in patients with Behçet disease.
J Gastroenterol Hepatol. 2020 Jan 30.
Hisamatsu T, Matsumoto T, Hibi T, et al. Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study).
J Crohns Colitis. 2019Sep 19;13(9):1097-1104. doi: 10.1093/ecco-jcc/jjz030.
Sands BE, Sandborn WJ, Hisamatsu T, Marano C, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2019 Sep 26;381(13):1201-1214.
Saito D, Hayashida M, Sato T, Minowa S, Ikezaki O, Mitsui T, Miura M, Sakuraba A, Hisamatsu T. Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy.
Intest Res. 2018 Apr;16(2):273-281. doi: 10.5217/ir.2018.16.2.273.
Watanabe K, Matsumoto T, Hisamatsu T, et al. Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn's disease.
Clin Gastroenterol Hepatol. 2018 Apr;16(4):542-549.
Nakase H, Motoya S, Hisamatsu T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Aliment Pharmacol Ther. 2017 Nov;46(9):873-882.
Matsumoto T, Motoya S, Hisamatsu T, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: A prospective, randomized trial.
J Crohns Colitis. 2016 Nov;10(11):1259-1266.
Umeno J, Hisamatsu T, Matsumoto T, et al. A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter.
PLoS Genetics 2015 Nov 5;11(11):e1005581.
Uo M, Hisamatsu T, Hibi T, et al. Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14+ macrophage activation.
Gut. 2013 Dec;62(12):1734-44.
Hisamatsu T, Okamoto S, Hibi T, et al. Novel, Objective, Multivariate Biomarkers Composed of Plasma Amino Acid Profiles for the Diagnosis and Assessment of Inflammatory Bowel Disease.
PLoS ONE. 2012;7(1):e31131.
Andou A, Hisamatsu T, Hibi T, et al. Dietary Histidine Ameliorates Murine Colitis by Inhibition of Proinflammatory Cytokine Production from Macrophages.
Gastroenterology. 2009 Feb;136(2):564-74.
Kamada N, Hisamatsu T, Hibi T, et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN- axis.
J Clin Invest. 2008 Jun;118(6):2269-80.
Hisamatsu T, Suzuki M, Podolsky DK. Interferon-gamma augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells.
J Biol Chem. 2003 Aug 29;278(35):32962-8.
Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells.
Gastroenterology. 2003 Apr;124(4):993-1000.
Hisamatsu T, Watanabe M, Hibi T, et al. Interferon-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis.
Cancer Res. 1999 Dec 1;59(23):5927-31.
所属学会 日本内科学会（評議員）
日本消化器病学会（理事，財団評議員，関東支部会評議員）
日本消化器内視鏡学会（社団評議員，関東支部会評議員）
日本炎症性腸疾患学会（副理事長，代議員）
日本消化器免疫学会（理事，評議員）
日本小腸学会（理事）
日本臨床免疫学会（理事，代議員）
日本消化管学会（理事，代議員）
日本大腸肛門病学会（評議員）
日本カプセル内視鏡学会（理事，代議員）
日本高齢消化器病学会（理事，評議員）
日本癌学会
日本臨床腫瘍学会
日本免疫学会
日本ヘリコバクター学会
日本肝臓病学会
日本胆道学会
日本膵臓学会
日本潰瘍学会
日本臨床疫学学会
慶應医師会
三鷹医師会
東京都医師会
日本医師会

American College of Gastroenterology (ACG)
The American Gastroenterological Association (AGA)
The American Association of Immunologist (AAI)
Society of Mucosal Immunology (SMI)
Asian Organization for Crohn's & Colitis (AOCC)
European Crohn's and Colitis Organization (ECCO)
公的な委員会等の役員・委員歴 厚生労働省科学研究費難治性疾患政策研究事業　難治性炎症性腸管障害に関する調査研究　研究代表者（2020-2022)（2023-2025）

日本学術振興会科学研究費委員会専門委員（2012-2013,2013-2014,2020-2021,2021- 2022）

日本学術振興会特別研究員等審査会専門委員（2015-2016，2016.-2017）

日本学術振興会国際事業委員会書面審査委員・書面評価員（2015-2016，2016.-2017）

国立研究開発法人日本医療研究開発機構外部有識者（査読委員）（2016-2017,2017-2018,2018-2019）

厚生労働省保険医療材料専門組織保険医療専門審査員 (2016-2018,2018-2020,2020-2022,2023-2025, 2025-)

文部科学省大学設置・学校法人審議会大学設置分科会医専門委員会専門員（2017-2018,2018-2019,2019-2020)

大学改革支援・学位授与機構学位審査委員会専門委員（2018-）

東京都指定難病審査会委員・難病患者認定審査会委員
学外活動2006年- 東京歯科大学市川総合病院消化器科非常勤講師
2015年- 同　客員教授

2015年- 慶應義塾大学医学部内科学（消化器）客員教授

2025年- 東京医科大学消化器内科学客員教授
学生のみなさんへ 杏林大学医学部で良医の育成に尽力したいと思います。思考力と想像力が医学生には大事だと思います。学生さんや若手医師たちには臆せずどんどん新しいことに挑戦して欲しいです。
関連サイト 杏林大学医学部消化器内科学教室
このページのトップへ

PAGE TOP